Drug Profile
Research programme: viral vaccines - Okairos AG
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Okairos AG
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections; Marburg virus disease
- Discontinued Cytomegalovirus infections; Human papillomavirus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Italy
- 04 Nov 2017 No recent reports of development identified for preclinical development in Marburg virus disease(Prevention) in Italy
- 29 May 2013 Okairos has been acquired by GlaxoSmithKline